LexaGene Hires First Direct Sales Executives and announces exercise of warrants
July 14 2020 - 7:58AM
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the
“
Company”), a molecular diagnostics company that
develops genetic analyzers for rapid pathogen detection, is pleased
to announce the hiring of its first wave of salespeople to support
the commercial launch of MiQLab™ prior to the end of September
2020.
Dr. Jack Regan, LexaGene’s CEO and Founder, states, “To start,
we’ve hired a Director of Clinical Sales and a Veterinary Sales
Representative. Both have a wealth of experience in their
respective fields and will begin working full time for LexaGene. We
will continue to hire additional salespeople later in the summer
and early fall. It’s very exciting to be at the stage where our
first sales are right around the corner.”
Our Director
of Clinical Sales has worked in the industry
for over 15 years at Alere Inc. and Cepheid, selling PCR
systems for point-of-care testing and molecular tests for
respiratory disease detection and sexually transmitted diseases
such as HIV, chlamydia, and gonorrhea. In 2017, Alere was acquired
by Abbott Laboratories for $5.3B1. In 2016, Cepheid
was acquired by Danaher Corporation for
$4B2.
Our Veterinary Sales Specialist has worked within the veterinary
industry for the last 17 years, most notably for IDEXX Laboratories
for the past four years.
Dr. Regan went on to say, “Based on their existing relationships
and proven track records in their specialty fields, I think both
salespeople will be excellent additions to the team. Having
specialists with experience at these leading companies and in the
field will prove an invaluable addition to the Company. We are
thrilled that we are able to continue to attract such high caliber
people to join LexaGene.”
LexaGene is also pleased to announce that 99% of the warrants
that were set to expire on June 29, 2020 were exercised. The
proceeds from these 4,375,271 warrants brought in CAD$2.8M to the
treasury. These monies are being used to support general
manufacturing and commercial operations.
As previously announced, LexaGene will be hosting a webinar to
provide additional information as well as a general corporate
overview at 2 PM EST on July 14, 2020. All are invited to register
for the webinar at this link:
https://event.webcasts.com/starthere.jsp?ei=1294081&tp_key=b029bb1560.
To be added to the LexaGene email list, please subscribe on the
Company website.
1
https://www.massdevice.com/official-abbott-closes-5b-alere-buy/2
https://investors.danaher.com/2016-09-06-Danaher-To-Acquire-Cepheid-For-53-00-Per-Share-Or-Approximately-4-Billion
On Behalf of the Board of Directors Dr. Jack Regan Chief
Executive Officer & Director
About LexaGene Holdings Inc. LexaGene is a
molecular diagnostics company that develops genetic analyzers for
pathogen detection and other molecular markers for on-site rapid
testing in veterinary diagnostics, food safety and for use in
open-access markets such as clinical research, agricultural testing
and biodefense. End-users simply need to collect a sample, load it
onto the instrument with a sample preparation cartridge, enter
sample ID and press ‘go’. The MiQLab analyzer delivers excellent
sensitivity, specificity, and breadth of detection and can return
results in approximately one hour. The unique open-access feature
is designed for custom testing so that end-users can load their own
real-time PCR assays onto the instrument to target any genetic
target of interest.
For further information, please contact:
Media Contacts Nicole Ridgedale Director of
Corporate Marketing, LexaGene 800.215.1824 ext
206 nridgedale@lexagene.com
Investor Relations Jay Adelaar Vice President
of Capital Markets, LexaGene 800.215.1824 ext
207 jadelaar@lexagene.com
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking information, which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectation. Important factors -- including the availability of
funds, the results of financing efforts, the success of technology
development efforts, the cost to procure critical parts,
performance of the instrument, market acceptance of the technology,
regulatory acceptance, and licensing issues -- that could cause
actual results to differ materially from the Company's expectations
as disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The company disclaims
any intention or obligation, except to the extent required by law,
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jul 2023 to Jul 2024